94 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
, 2023, there were 75,370,977 common shares and 2,173,081 pre-funded warrants outstanding.
Research and development expenses were $41.1 million … , respectively. The increase in research and development expenses for the year was primarily attributable to expenses related to Xenon's enrollment
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
partnered products and product candidates are dependent upon the research, development and marketing efforts of our collaborators.
S-3
Our reliance … to incur significant research and development and other expenses related to our clinical development and ongoing operations. As a result, we
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
of our partnered products and product candidates are dependent upon the research, development and marketing efforts of our collaborators.
S-3
Our … product sales to date, and we will continue to incur significant research and development and other expenses related to our clinical development
8-K
EX-99.1
h96qk le5afu
8 Nov 23
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
zrhl5n 39
9 Aug 23
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:16pm
8-K
EX-99.1
4gwd8 w7d
9 May 23
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
p3yzw2nzeaibxk2
8 Nov 22
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:07pm
424B5
o8u2vqt24g0vqo2u3
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
81tnd1n82h0ob y8yg
22 Jun 22
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
ny7bdkxinqwbm
10 May 22
Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:16pm
424B5
p75n7
1 Mar 22
Prospectus supplement for primary offering
5:12pm